CM336 for relapsed or refractory autoimmune cytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with one of these conditions: immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed AIHA, or Evans syndrome.
- Your disease has come back after treatment or hasn't responded well to prior treatments.
- You have not received any treatment that targets the BCMA protein on immune cells.
- You are otherwise healthy enough for the study (your doctor will check this) and can follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This study tests an investigational drug called CHT105, given as an injection, for people with immune thrombocytopenia (ITP) that has not responded to or has come back after prior treatments. The goal is to see if it can help improve platelet counts and manage the disease.
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Hear when a new Autoimmune Cytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.